Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) - guidance (TA594)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
14 August 2019

Abstract

NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults because Takeda did not provide an evidence submission. We will review this decision if the company decides to make a submission.

Guidance development process

How we develop NICE technology appraisal guidance